Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer

Nature Communications

Volumn 5, Issue , 2014, Pages

  Nilsson, Roland ^a   Jain, Mohit ^b,c,d,e,h   Madhusudhan, Nikhil ^b,c,d   Sheppard, Nina Gustafsson ^a   Strittmatter, Laura ^b,c,d   Kampf, Caroline ^f   Huang, Jenny ^g   Asplund, Anna ^f   Mootha, Vamsi K ^b,c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID; MESSENGER RNA; MTHFD2 PROTEIN; PROTEIN; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; HYDROLASE; METHYLENE TETRAHYDROFOLATE DEHYDROGENASE-METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MULTIENZYME COMPLEX;

AMINO ACID; CANCER; CARBON; EMBRYONIC DEVELOPMENT; ENZYME ACTIVITY; GENE EXPRESSION; META-ANALYSIS; METABOLISM; MITOCHONDRION; RNA; TUMOR;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARBON METABOLISM; CELL PROLIFERATION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; MITOCHONDRION; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; TRANSFORMED CELL; CELL DEATH; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RNA INTERFERENCE; TRANSFORMED CELL LINE;

AMINOHYDROLASES; CELL DEATH; CELL LINE, TRANSFORMED; CELL PROLIFERATION; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MITOCHONDRIA; MULTIENZYME COMPLEXES; NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER;

EID: 84897414311     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4128     Document Type: Article

References (46)

1. Warburg, O. Über den Stoffwechsel der Carcinomzelle. Naturwissenschaften 12, 1131-1137 (1924).
2. Ben-Haim, S. & Ell, P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J. Nucl. Med. 50, 88-99 (2009).
3. Tennant, D. A., Durán, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277 (2010).
4. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
5. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
6. Zhang, W. C. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259-272 (2012).
7. Weber, G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res. 43, 3466-3492 (1983).
8. Weinhouse, S. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes Memorial Lecture. Cancer Res. 32, 2007-2016 (1972).
9. Hu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522-529 (2013).
10. Liu, F., White, J. A., Antonescu, C. & Quackenbush, J. GCOD-genechip oncology database. BMC bioinformatics 12, 46 (2011).
11. Rhodes, D. R. et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl Acad. Sci. USA 101, 9309-9314 (2004).
12. Whitfield, M. L. et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977-2000 (2002).
13. Cho, R. J. et al. Transcriptional regulation and function during the human cell cycle. Nat. Genet. 27, 48-54 (2001).
14. Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl Acad. Sci. USA 104, 1777-1782 (2007).
15. Altenberg, B. & Greulich, K. O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84, 1014-1020 (2004).
16. Hofbauer, K.-H. et al. Oxygen tension regulates the expression of a group of procollagen hydroxylases. Eur. J. Biochem. 270, 4515-4522 (2003).
17. Dennis, J. W., Granovsky, M. & Warren, C. E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta. 1473, 21-34 (1999).
18. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008).
19. Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350 (2011).
20. Noda, K. et al. Elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res. 63, 6282-6289 (2003).
21. Liu, W. et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl Acad. Sci. USA 109, 8983-8988 (2012).
22. De Ingeniis, J. et al. Functional specialization in proline biosynthesis of melanoma. PLoS One 7, e45190 (2012).
23. Hagedorn, C. H. & Phang, J. M. Transfer of reducing equivalents into mitochondria by the interconversions of proline and delta1-pyrroline-5-carboxylate. Arch. Biochem. Biophys. 225, 95-101 (1983).
24. Krishnan, N., Dickman, M. B. & Becker, D. F. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic. Biol. Med. 44, 671-681 (2008).
25. Reversade, B. et al. Mutations in PYCR1 cause cutis laxa with progeroid features. Nat. Genet. 41, 1016-1021 (2009).
26. Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040-1044 (2012).
27. Tibbetts, A. S. & Appling, D. R. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu. Rev. Nutr. 30, 57-81 (2010).
28. Mejia, N. R. & MacKenzie, R. E. NAD-dependent methylenetetrahydrofolate dehydrogenase is expressed by immortal cells. J. Biol. Chem. 260, 14616-14620 (1985).
29. Di Pietro, E., Sirois, J., Tremblay, M. & MacKenzie, R. Mitochondrial NAD-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase is essential for embryonic development. Mol. Cell Biol. 22, 4158 (2002).
30. Smith, G. K. et al. Activity of an NAD-dependent 5,10-methylenetetrahydrofolate dehydrogenase in normal tissue, neoplastic cells, and oncogene-transformed cells. Arch. Biochem. Biophys. 283, 367-371 (1990).
31. Patel, H., Pietro, E. D. & MacKenzie, R. E. Mammalian fibroblasts lacking mitochondrial NAD+-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase are glycine auxotrophs. J. Biol. Chem. 278, 19436-19441 (2003).
32. Lehtinen, L., Ketola, K., Mäkelä, R. & Mpindi, J. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget 4, 48-63 (2013).
33. Weir, D. G. & Scott, J. M. The methyl folate trap. Lancet 318, 337-340 (1981).
34. Linster, C. L., Van Schaftingen, E. & Hanson, A. D. Metabolite damage and its repair or pre-emption. Nat. Chem. Biol. 9, 72-80 (2013).
35. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289-300 (1995).
36. Subramanianan, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
37. Su, A. I. et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 101, 6062-6067 (2004).
38. Kampf, C., Olsson, I., Ryberg, U., Sjöstedt, E. & Pontén, F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J. Vis. Exp. 63, e3620 (2012).
39. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer cell 10, 529-541 (2006).
40. Van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
41. Desmedt, C. et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13, 3207-3214 (2007).
42. Pawitan, Y. et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7, R953-R964 (2005).
43. Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 102, 13550-13555 (2005).
44. Kao, K.-J., Chang, K.-M., Hsu, H.-C. & Huang, A. T. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11, 143 (2011).
45. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Ser. B Stat. Methodol. 34, 187-220 (1972).
46. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188 (1986).